New tuberculosis therapeutics: a growing pipeline

Area of Science:

• Microbiology and Infectious Diseases
• Drug Discovery and Development
• Public Health

Background:

• Tuberculosis (TB) remains a significant global health challenge, particularly in developing nations.
• Current treatment regimens for drug-susceptible TB, drug-resistant TB, TB/HIV coinfection, and latent TB infection are inadequate.
• A critical need exists for novel chemotherapeutic agents to enhance TB control efforts.

Purpose of the Study:

• To highlight the urgent need for novel antitubercular drugs.
• To review the current landscape of TB drug research and development.
• To discuss promising avenues for future TB therapeutics.

Main Methods:

• Review of ongoing clinical trials for new TB drug candidates.
• Exploration of preclinical investigations into existing antibiotic classes for antitubercular activity.
• Identification and validation of novel molecular targets for TB treatment.

Main Results:

• Seven novel compounds are currently in clinical development specifically for TB treatment.
• Preclinical research is investigating known antibiotic families for new antitubercular applications.
• Novel molecular targets are being identified and validated for therapeutic potential.

Conclusions:

• Recent advancements in TB drug research and development offer significant hope for improved treatment outcomes.
• The pipeline of new TB drugs, including compounds in clinical trials and novel targets, is encouraging.
• Continued investment in research is crucial for developing effective therapies against all forms of TB.